[1]雷 锐a,殷 实a,李 志b.急性冠脉综合征患者血清sST2 及NLRP3 水平与介入术后无复流- 慢血流的相关性分析[J].现代检验医学杂志,2024,39(04):121-125+154.[doi:10.3969/j.issn.1671-7414.2024.04.022]
　LEI Ruia,YIN Shia,LI Zhib.Correlation Analysis between Serum sST2 and NLRP3 Levels in Patients with Acute Coronary Syndrome and No Reflow or Slow Re-Flow after Interventional Surgery[J].Journal of Modern Laboratory Medicine,2024,39(04):121-125+154.[doi:10.3969/j.issn.1671-7414.2024.04.022]
点击复制

急性冠脉综合征患者血清sST2 及NLRP3 水平与介入术后无复流- 慢血流的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
121-125+154
栏目:
论著
出版日期:
2024-07-15

文章信息/Info

Title:
Correlation Analysis between Serum sST2 and NLRP3 Levels in Patients with Acute Coronary Syndrome and No Reflow or Slow Re-Flow after Interventional Surgery
文章编号:
1671-7414（2024）04-121-06
作者:
雷 锐a; 殷 实a; 李 志b
（佳木斯市中心医院 a. 心内三科；b. 心内二科，黑龙江佳木斯 154002）
Author(s):
LEI Ruia;  YIN Shia;  LI Zhib
(a. the Third Department of Cardiology; b. the Second Department of Cardiology, Jiamusi Central Hospital, Heilongjiang Jiamusi 154002, China)
关键词:
急性冠脉综合征; 经皮冠状动脉介入术; 无复流- 慢血流; 可溶性生长刺激表达基因蛋白2; 核苷酸寡聚化结构域样受体热蛋白结构域相关蛋白3
分类号:
R541.4；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.04.022
文献标志码:
A
摘要:
目的 探讨急性冠脉综合征(acute coronary syndrome,Acs) 患者血清可溶性生长刺激表达基因蛋白2（solublegrowth stimulation expression gene 2 protein，sST2），核苷酸寡聚化结构域样受体热蛋白结构域相关蛋白3（nucleotideoligomerization domain like receptor heat protein domain associated protein 3，NLRP3） 水平与经皮冠状动脉介入治疗（percutaneous coronary intervention，PCI）术后无复流- 慢血流的关系。方法 选择2020 年1 月~2022 年12 月佳木斯市中心医院收治的97 例急性冠脉综合征患者，所有患者均接受PCI 治疗，根据术后无复流- 慢血流发生情况分为无复流-慢血流组（n=20）和对照组（n=77）。术前检测血清sST2 及NLRP3 水平，分析影响急性冠脉综合征患者PCI 术后无复流-慢血流的因素以及sST2，NLRP3 预测急性冠脉综合征患者PCI 术后无复流- 慢血流的价值。结果 无复流- 慢血流组血清sST2（14.32±2.65 ng/ml vs 11.02±2.13 ng/ml），NLRP3（68.23±10.17 pg/ml vs 42.05±8.23 pg/ml）水平高于对照组, 差异具有统计学意义（t=5.860，12.055，均P ＜ 0.05）。多因素Logistic 回归分析显示高血栓负荷（OR:7.791,95%CI:2.834~21.421）、高水平sST2（OR=2.071，95%CI：1.146 ～ 3.743）、高水平NLRP3（OR=2.008，95%CI：1.228 ～ 3.284）是急性冠脉综合征患者PCI 术后无复流- 慢血流的危险因素（均P ＜ 0.05）。sST2，NLRP3 诊断急性冠脉综合征患者PCI 术后无复流- 慢血流的临界值分别为12.91ng/ml，55.39 pg/ml，曲线下面积分别为0.737，0.686，联合sST2，NLRP3 诊断急性冠脉综合征患者PCI 术后无复流- 慢血流的曲线下面积为0.907，高于单独诊断（Z=2.662，2.856，均P ＜ 0.05）。结论 急性冠脉综合征患者血清sST2，NLRP3 水平增高与PCI 术后无复流- 慢血流的发生有关，联合检测sST2 和NLRP3 可提高对术后无复流- 慢血流的诊断效能。
Abstract:
Objective To investigate the relationship between serum soluble growth stimulation expression gene 2 protein (sST2) and nucleotide oligomerization domain like receptor heat protein domain associated protein 3 (NLRP3) levels in patients with acute coronary syndrome(ACS) and postoperative no reflow or slow re-flow after percutaneous coronary intervention (PCI). Methods A total of 97 patients with acute coronary syndrome admitted to Jiamusi Central Hospital from January 2020 to December 2022 were selected. All patients received PCI treatment and were divided into no reflow or slow re-flow group (n=20) and control group (n=77) based on the occurrence of postoperative no reflow or slow re-flow. The serum levels of sST2 and NLRP3 were detected before surgery, and the factors affecting no reflow or slow re-flow in patients with acute coronary syndrome after PCI were analyzed. The value of sST2 and NLRP3 in predicting no reflow or slow re-flow in patients with acute coronary syndrome after PCI was also analyzed. Results The serum levels of sST2 (14.32 ± 2.65 ng/ml vs 11.02 ± 2.13 ng/ml) and NLRP3 (68.23 ± 10.17 pg/ml vs 42.05 ± 8.23 pg/ml) in the no reflow or slow re-flow group were higher than those in the control group,and the differences were statistically significant (t=5.860, 12.055, all P<0.05). Multivariate logistic regression analysis showed that high thrombotic burden(OR=7.791, 95% CI:2.834~21.421), high levels of sST2 (OR=2.071, 95%CI=1.146~3.743), and high levels of NLRP3 (OR=2.008, 95% CI: 1.228~3.284) were risk factors for no reflow or slow re-flow in patients with acute coronary syndrome after PCI (all P<0.05). The critical values of sST2 and NLRP3 for diagnosing no reflow or slow re-flow in patients with acute coronary syndrome after PCI were 12.91 ng/ml and 55.39 pg/ml, with areas under the curve of 0.737 and 0.686, respectively. The area under the curve of combined with sST2 and NLRP3 for diagnosing no reflow or slow reflow in patients with acute coronary syndrome after PCI was 0.907, which was higher than that of individual diagnosis (Z=2.662, 2.856, all P<0.05). Conclusion The elevated levels of serum sST2 and NLRP3 in patients with acute coronary syndrome were related to the occurrence of no reflow or slow re-flow after PCI. The combination of sST2 and NLRP3 could improve the diagnostic efficacy of postoperative no reflow or slow blood flow.

参考文献/References:

[1] 丁锦, 贯芳, 梁小涵, 等. 急性冠脉综合征患者血浆外泌体NEAT1, miR-204 和MMP-9 的表达水平及临床意义[J]. 现代检验医学杂志, 2023, 38(1): 59-65. DING Jin, GUAN Fang, LIANG Xiaohan, et al. Expression levels and clinical significance of plasma exosomal NEAT1, miR-204 and MMP-9 in patients with acute coronary syndrome[J]. Journal of Modern Laboratory Medicine, 2023, 38(1): 59-65.
[2] WANG Le, CONG Hongliang, ZHANG Jingxia, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome[J]. Cardiovascular Diabetology, 2020, 19(1): 80.
[3] FAJAR J K, HERIANSYAH T, ROHMAN M S. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis[J]. Indian Heart Journal, 2018, 70 (Suppl 3): S406-S418.
[4] 刘艳杰, 高宇平, 赵晨. STEMI 病人急诊介入无复流- 慢血流危险因素及高危病变特征分析[J]. 中西医结合心脑血管病杂志, 2020, 18(12): 1935-1939. LIU Yanjie, GAO Yuping, ZHAO Chen. Analysis of risk factors of no reflow-slow flow and characteristics of high risk lesions in patients with STEMI after emergency intervention[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2020, 18(12): 1935-1939.
[5] ALEKSOVA A, PALDINO A, BELTRAMI A P, et al. Cardiac biomarkers in the emergency department: the role of soluble ST2 (sST2) in acute heart failure and acute coronary syndrome-there is meat on the bone[J]. Journal of Clinical Medicine, 2019, 8(2): 270.
[6] SUN Yuan, PAVEY H, WILKINSON I, et al. Role of the IL-33/ST2 axis in cardiovascular disease: asystematic review and meta-analysis[J]. PLoS One, 2021, 16(11): e0259026.
[7] TAKAHASHI M. NLRP3 inflammasome as a key driver of vascular disease[J]. Cardiovascular Research, 2022, 118(2): 372-385.
[8] 中国医师协会急诊医师分会, 国家卫健委能力建设与继续教育中心急诊学专家委员会, 中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南(2019)[J]. 临床急诊杂志, 2019,20(4): 253-262. Emergency Doctor Branch of Chinese Medical Doctor Association, Committee of Emergency Medicine Experts of National Health Commission Capacity Building and Continuing Education Center, Emergency First Aid Branch of China International Exchange and Promotive Association for Medical Healthcare. Guidelines for rapid emergency diagnosing acute coronary syndrome[J]. Journal of Clinical Emergency, 2019, 20(4): 253-262.
[9] HU Xiangming, YANG Xing, LI Xida, et al. Elevated uric acid is related to the no-/slow-reflow phenomenon in STEMI undergoing primary PCI[J]. European Journal of Clinical Investigation, 2022, 52(4): e13719.
[10] KAUR G, BAGHDASARYAN P, NATARAJAN B, et al. Pathophysiology, diagnosis, and management of coronary no-reflow phenomenon[J]. International Journal of Angiology, 2021, 30(1): 15-21.
[11] CAIAZZO G, MUSCI R L, FREDIANI L, et al. State of the art: no-reflow phenomenon[J]. Cardiology Clinics, 2020, 38(4): 563-573.
[12] LI Junpei, CAO Tianyu, WEI Yaping, et al. A review of novel cardiac biomarkers in acute or chronic cardiovascular diseases: the role of soluble ST2 (sST2), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), and procalcitonin (PCT)[J]. Disease Markers, 2021, 2021: 6258865.
[13] 蒋美燕, 黄恒贵, 袁仕国. QRS 波群时限联合血清angptl2, angpt17, sST2 对急性心力衰竭患者短期预后的评估价值[J]. 天津医药, 2023, 50(10)： 1136-1140. JIANG Meiyan, HUANG Henggui, YUAN Shiguo. Evaluation value of QRS complex time limit combined with serum angptl2, angpt17 and sST2 for short-tern prognosis of patients with acute heart failure[J]. Tianjin Medical Journal, 2023, 50(10): 1136-1140.
[14] GU Linlin, LI Jing. Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis[J]. Bioscience Reports, 2019, 39(6): BSR20182441.
[15] SOMUNCU M U, AKGUN T, CAKIR M O, et al. The elevated soluble ST2 predicts no-reflow phenomenon in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Journal of Atherosclerosis and Thrombosis, 2019, 26(11): 970-978.
[16] ZHOU Wenyi, CHEN Chunyuan, CHEN Zhiheng, et al. NLRP3: a novel mediator in cardiovascular disease[J]. Journal of Immunology Research, 2018, 2018: 5702103.
[17] XUE Chao, CHEN Qizhi, BIAN Ling, et al. The relationships between cholesterol crystals, NLRP3 inflammasome, and coronary atherosclerotic plaque vulnerability in acute coronary syndrome: an optical coherence tomography study[J]. Frontiers in Cardiovascular Medicine, 2022, 9: 905363.
[18] AFRASYAB A, QU Peng, ZHAO Yang, et al. Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients[J]. Heart and Vessels, 2016, 31(8): 1218-1229.
[19] YU Ping, LI Yuangeng, FU Wenwen, et al. Panax quinquefolius L. Saponins protect myocardial ischemia reperfusion no-reflow through inhibiting the activation of NLRP3 inflammasome via TLR4/MyD88/NF-κB signaling pathway[J]. Frontiers in Pharmacology, 2020, 11: 607813.
[20] NIE Chaoqun, DING Xue, A Rong, et al. Hydrogen gas inhalation alleviates myocardial ischemia-reperfusion injury by the inhibition of oxidative stress and NLRP3-mediated pyroptosis in rats[J]. Life Sciences, 2021, 272: 119248.

相似文献/References:

[1]杨 阳,吴 嘉,汪俊军.FIB和D-二聚体联合GRACE评分与急性冠脉综合征的风险预测[J].现代检验医学杂志,2017,32(01):99.[doi:10.3969/j.issn.1671-7414.2017.01.027]
　YANG Yang,WU jia,WANG Jun-jun.FIB and D-D with GRACE Risk Score to Predict the Risk of Acute Coronary Syndrome[J].Journal of Modern Laboratory Medicine,2017,32(04):99.[doi:10.3969/j.issn.1671-7414.2017.01.027]
[2]刘永玲a,罗厚龙b,刘行超b,等.血清SOD和hsCRP等指标在急性冠脉综合征中的应用及相关性分析[J].现代检验医学杂志,2017,32(06):115.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　LIU Yong-linga,LUO Hou-longb,LIU Xing-chaob,et al.Level and Correlationship of Serum SOD and hsCRP and Other Indicators in Acute Coronary Syndrome[J].Journal of Modern Laboratory Medicine,2017,32(04):115.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]秦绪珍a,王丹晨a,叶益聪b,等.血清多种生化指标在PCI患者围术期的浓度变化[J].现代检验医学杂志,2018,33(01):35.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　QIN Xu-zhena,WANG Dan-chena,YE Yi-congsup>b,et al.Perioperative Changes of Serum Biochemical Markers in Patients with PCI[J].Journal of Modern Laboratory Medicine,2018,33(04):35.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[4]程 涛,黄 刚.血清miRNA-21,miRNA-126表达在诊断PCI术后冠状动脉再狭窄的临床应用价值[J].现代检验医学杂志,2018,33(01):59.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　CHENG Tao,HUANG Gang.Clinical Value of Serum miRNA-21 and miRNA-126 Expression in Diagnosis of the Coronary Artery Restenosis after PCI[J].Journal of Modern Laboratory Medicine,2018,33(04):59.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[5]刘英华a,王玉霞a,卢海英b,等.急性冠脉综合征患者血清LncRNA XIST 和miR-330-3p 水平表达与心脏自主神经功能的相关性研究[J].现代检验医学杂志,2022,37(04):64.[doi:10.3969/j.issn.1671-7414.2022.04.013]
　LIU Ying-huaa,WANG Yu-xiaa,LU Hai-yingb,et al.Correlation between the Expression of Serum LncRNA XIST and miR-330-3p Levels and Cardiac Autonomic Nerve Function in Patients with Acute Coronary Syndrome[J].Journal of Modern Laboratory Medicine,2022,37(04):64.[doi:10.3969/j.issn.1671-7414.2022.04.013]
[6]周 倩,陈 诚,陈智龙.急性冠脉综合征患者血清miR-361-5p 和COMP 表达水平及其与短期预后的相关性研究[J].现代检验医学杂志,2022,37(05):105.[doi:10.3969/j.issn.1671-7414.2022.05.021]
　ZHOU Qian,CHEN Cheng,CHEN Zhi-long.Study of Serum miR-361-5p and COMP Expression Levels in Patients with Acute Coronary Syndrome and Their Correlation with Short-term Prognosis[J].Journal of Modern Laboratory Medicine,2022,37(04):105.[doi:10.3969/j.issn.1671-7414.2022.05.021]
[7]丁 锦a,贯 芳b,梁小涵c,等.急性冠脉综合征患者血浆外泌体NEAT1，miR-204 和MMP-9 的表达水平及临床意义[J].现代检验医学杂志,2023,38(01):59.[doi:10.3969/j.issn.1671-7414.2023.01.012]
　DING Jina,GUAN Fangb,LIANG Xiao-hanc,et al.Expression Levels and Clinical Significance of Plasma Exosomal NEAT1, miR-204 and MMP-9 in Patients with Acute Coronary Syndrome[J].Journal of Modern Laboratory Medicine,2023,38(04):59.[doi:10.3969/j.issn.1671-7414.2023.01.012]

备注/Memo

备注/Memo:
基金项目：黑龙江卫生健康委科研课题（2020-368）。
作者简介：雷锐（1982-），女，硕士研究生，副主任医师，研究方向：心血管疾病，leirui98464@126.com。
通讯作者：李志（1982-），男，硕士研究生，副主任医师，研究方向：心血管疾病。
更新日期/Last Update: 2024-07-15